Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide for Parkinsonian Variant of Multiple System Atrophy
NCT03753763Phase 2Completed
- Sponsor
- Zambon
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of safinamide in multiple system atrophy (MSA), sponsored by Zambon. Started Oct 2019; status: completed.
02
Drugs
safinamide
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT03753763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03753763.